Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control. At present, the standard of treatment in patients with type 2 diabetes is that all medication is stopped in the immediate postoperative period and only re-started if symptoms of diabetes re-emerge. Although a large proportion of patients with diabetes will initially go in to remission, 80% experience relapse within five years. This study is needed to determine whether continuing medications is not only safe but will improve long term outcomes for patients with diabetes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | Active Comparator | Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy. Long term diabetes care will be under the supervision of their primary care provider/general practitioner |
|
| Intervention | Experimental | Patients will undergo bariatric surgery- either roux en y gastric bypass or sleeve gastrectomy and will have ongoing goal directed medical treatment for their T2DM, titrated to specific end points for BP, HbA1c and lipids. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bariatric surgery + goal directed medical therapy | Procedure | Patients will undergo bariatric surgery (RYGB or SG) with goal directed medical therapy titrated to specific end points for BP, HbA1c and lipids |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients in each group reaching the composite end point | BP<130/80, HbA1c<6.5%, LDL<2.6mmol/L | 5 years |
| Proportion of patients reaching end point for glycemic control | HbA1c<6.5% | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Change in body weight | Change in body weight from baseline (kg) | 5 years |
| Change in BMI | Change in BMI from baseline (kg/m2) | 5 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alexander Miras, MRCP | Contact | : +44 (0)20 8383 3242 | a.miras@nhs.net |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University College Dublin | Recruiting | Dublin | Ireland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35879015 | Derived | Sudlow A, Miras AD, Cohen RV, Kahal H, Townley J, Heneghan H, Le Roux C, Pournaras DJ. Medication following bariatric surgery for type 2 diabetes mellitus (BY-PLUS) study: rationale and design of a randomised controlled study. BMJ Open. 2022 Jul 25;12(7):e054313. doi: 10.1136/bmjopen-2021-054313. |
Not provided
Not provided
The authors shall make data available to the scientific community with as few restrictions as feasible, ensuring anonymisation, while retaining exclusive use until the publication of major outputs.
6 months
Free access
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D050110 | Bariatric Surgery |
| ID | Term |
|---|---|
| D049088 | Bariatrics |
| D000073319 | Obesity Management |
| D013812 | Therapeutics |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
Patients will be randomly allocated to the control arm (bariatric surgery- either RYGB or SG) or intervention (bariatric surgery- either RYGB or SG + goal directed medical therapy for t2DM)
Not provided
Not provided
Not provided
Not provided
| Bariatric surgery | Procedure | Patients will undergo bariatric surgery (RYGB or SG) with usual care for diabetes mellitus undertaken by their primary care provider/general practitioner |
|
| Change in waist circumference | Change in waist circumference (cm) | 5 years |
| Change in lipid control | Proportion of patients achieving good lipid control (LDL<2.6mmol/L) | 5 years |
| Change in glycaemic control | Change in long term glycaemic control(HbA1c) | 5 years |
| Change in blood pressure | Proportion of patients achieving BP<130/80mmHg | 5 years |
| Change in liver function | Proportion of patients achieving normal liver function tests (ALT, GGT, ALP, AST) | 5 years |
| Change in renal function | Proportion of patients with normal renal function (plasma Cr, eGFR) | 5 years |
| Change in inflammatory markers | Reduction in CRP | 5 years |
| Change in urine albumin: creatinine ratio | Proportion of patients in each group with a uACR<30 | 5 years |
| Change in quality of life | Quality of life change as determined by SF-36 and MPH-H | 5 years |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D004700 | Endocrine System Diseases |